{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:49:05Z","timestamp":1789386545659,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6_suppl_4","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2004,3,23]]},"DOI":"10.1212\/wnl.62.6_suppl_4.s32","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T14:22:52Z","timestamp":1336918972000},"update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Practical considerations in the use of apomorphine injectable"],"prefix":"10.1212","volume":"62","author":[{"given":"Annette","family":"Bowron","sequence":"first","affiliation":[{"name":"From the Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","first-page":"251","volume":"76","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc. 1951; 76: 251\u2013253.","journal-title":"Trans Am Neurol Assoc"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197603112941101"},{"key":"e_1_3_2_4_2","first-page":"954","volume":"1","year":"1979","unstructured":"Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson\u2019s disease. Lancet. 1979; 1: 954\u2013956.","journal-title":"Lancet"},{"key":"e_1_3_2_5_2","first-page":"251","volume":"76","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc. 1951; 76: 251\u2013253.","journal-title":"Trans Am Neurol Assoc"},{"key":"e_1_3_2_6_2","first-page":"403","volume":"1","year":"1988","unstructured":"Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988; 1: 403\u2013406.","journal-title":"Lancet"},{"key":"e_1_3_2_7_2","first-page":"130.","volume":"15","year":"2000","unstructured":"Hutton JT, Dewey RB Jr, LeWitt PA, Factor SA. A randomized, double blind, placebo-controlled trial of subcutaneously-injected apomorphine for parkinsonian \u201coff\u201d states. Mov Disord. 2000; 15 (suppl 3): 130. Abstract.","journal-title":"Mov Disord"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.6.681"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(93)90128-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1993.tb00226.x"},{"key":"e_1_3_2_12_2","unstructured":"Parkinson\u2019s Disease Society.  Meeting a need? The role of the Parkinson\u2019s Disease Nurse Specialist.  London:  Parkinson\u2019s Disease Society 1994."},{"key":"e_1_3_2_13_2","first-page":"38","volume":"90","year":"1994","unstructured":"Calne S. Nursing care of patients with idiopathic parkinsonism. Nurs Times. 1994; 90: 38\u201339.","journal-title":"Nurs Times"},{"key":"e_1_3_2_14_2","unstructured":"Lees  AJ Turner  K Richardson  C.  Treatment of Parkinson\u2019s disease with apomorphine\u2014Shared Care Guidelines.  3rd ed.  University College London Hospitals NHS Trust 1999."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01376517-200102000-00004"},{"key":"e_1_3_2_16_2","unstructured":"Shared Care Guidelines 2002.  Chaudhuri KR Clough C Blockley A.  The use of apomorphine in Parkinson\u2019s disease.  1st ed.  King\u2019s College Hospital NHS Trust 2001."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.1999.60.11.1236"},{"key":"e_1_3_2_18_2","first-page":"529","volume":"80","year":"1999","unstructured":"MacMahon DG. Use of apomorphine in clinical practice. Adv Neurol. 1999; 80: 529\u2013533.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_19_2","unstructured":"Fahn  S Elton  RL and the UPDRS Development Committee.  The Unified Parkinson\u2019s Disease Rating Scale. In:   Fahn S Marsden CD Calne D eds.  Recent developments in Parkinson\u2019s disease.  New York:  MacMillan 1987:  153\u2013163."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530350045017"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080208"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.5.709"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.5.573"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1972.00490180010004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.4.492"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7132.641"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.9.1908"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1483"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050554"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<601::AID-MDS1003>3.0.CO;2-Q"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080208"},{"key":"e_1_3_2_33_2","first-page":"545","volume":"80","year":"1999","unstructured":"Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson\u2019s disease. Adv Neurol. 1999; 80: 545\u2013548.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1385"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.2.96"},{"key":"e_1_3_2_36_2","first-page":"656","volume":"60","year":"1993","unstructured":"Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Contin-uous subcutaneous apomorphine infusions for fluctuating Parkinson\u2019s disease. Long-term follow-up in 18 patients. Adv Neurol. 1993; 60: 656\u2013659.","journal-title":"Adv Neurol"},{"key":"e_1_3_2_37_2","first-page":"23","volume":"2","year":"2002","unstructured":"McGee P. Apomorphine treatment: a nurse\u2019s perspective. Adv Clin Neurosci Rehab. 2002; 2: 23\u201324.","journal-title":"Adv Clin Neurosci Rehab"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/full\/10.1212\/WNL.62.6_suppl_4.S32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:11:11Z","timestamp":1711638671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.62.6_suppl_4.S32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,23]]},"references-count":36,"journal-issue":{"issue":"6_suppl_4","published-print":{"date-parts":[[2004,3,23]]}},"alternative-id":["10.1212\/WNL.62.6_suppl_4.S32"],"URL":"https:\/\/doi.org\/10.1212\/wnl.62.6_suppl_4.s32","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,23]]}}}